The effects of hormone therapy on the markers of inflammation and endothelial function and plasma matrix metalloproteinase-9 level in postmenopausal women: The postmenopausal estrogen progestin intervention (PEPI) trial
Authors:
- Peifeng HuPHPeifeng Hu
- Gail A. GreendaleGGGail A. Greendale
- Shana L. PallaSPShana L. Palla
- Beth A. ReboussinBRBeth A. Reboussin
- David M. HerringtonDHDavid M. Herrington
- Elizabeth Barrett-ConnorEBElizabeth Barrett-Connor
- David B. ReubenDRDavid B. Reuben
- 1 April 2006
- journal article
- research article
- Published by Elsevier in Atherosclerosis
- Vol. 185 (2) , 347-352
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Endothelial functionThe American Journal of Cardiology, 2002
- Inflammatory Biomarkers, Hormone Replacement Therapy, and Incident Coronary Heart DiseaseJAMA, 2002
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Differential Effects of E and Droloxifene on C-Reactive Protein and Other Markers of Inflammation in Healthy Postmenopausal WomenThe Journal of Clinical Endocrinology & Metabolism, 2001
- Effect of Postmenopausal Hormones on Inflammation-Sensitive ProteinsCirculation, 1999
- Prospective Study of C-Reactive Protein and the Risk of Future Cardiovascular Events Among Apparently Healthy WomenCirculation, 1998
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998
- Matrix Metalloproteinases and Cardiovascular DiseaseCirculation Research, 1995
- Factors influencing the presence or absence of acute coronary artery thrombi in sudden ischaemic deathEuropean Heart Journal, 1989